Generic name: Recombinant Hepatitis E vaccine | Trade name: Hecolin®
Hecolin®, a ground-breaking vaccine for Hepatitis E, was launched in China in October 2012 by Xiamen Innovax Biotech, our subsidiary and the vaccine arm of the Yangshengtang Group. It’s the first vaccine against Hepatitis E that has been launched worldwide.
Each year an estimated 20 million Hepatitis E infections occur worldwide leading to more than 3.3million symptomatic cases of hepatitis E according to the World Health Organization.
Hecolin® was developed based on a core-platform using DNA recombinant technology to express protein in E. coli (Escherichia Coli) for vaccine production. This platform was developed in collaboration with the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD).
Hecolin® has been cleared for use by the China Food and Drug Administration and is currently licensed in China.
Hecolin® is suitable for susceptible population aged 16 and older. The product is recommended for individuals exposed to high risk of hepatitis E virus infection. Inoculation of this product can stimulate the body to produce protective immunity against hepatitis E.
